HILE will implement delisting risk warning from May 6, with its stock abbreviation changed to "*ST HILE".

Source: Hile Bio-Tech Announcement on Implementing Delisting Risk Warning and Trading Suspension

DentalGoodNews｜April 30, 2026, HILE announced that due to its audited total profit and net profit for 2025 both being negative, and its operating revenue falling below 300 million yuan, it has triggered the delisting risk warning threshold of the Shanghai Stock Exchange. The company's shares will be suspended from trading on April 30 for one day, and will be subject to a delisting risk warning starting May 6, with the stock abbreviation changing from "HILE" to "*ST HILE".

According to the announcement, HILE achieved operating revenue of approximately 188 million yuan in 2025, with a net profit attributable to shareholders of the parent company loss of 311 million yuan, and a net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses loss of approximately 616 million yuan. As previously reported by DENTALGOODNEWS (Leading Dental Industry Media, DGN), HILE had earlier issued a performance pre-loss announcement, estimating a net loss after deducting non-recurring gains and losses of approximately 620 million yuan for 2025, and had already warned of the potential risk of triggering a delisting risk warning.

In response to the imposition of the delisting risk warning, the board of directors of HILE stated that it will take active measures to seek its removal. Specific measures include strictly implementing the 2026 business plan, managing existing business operations well, striving to improve performance, and avoiding the recurrence of large-scale goodwill impairment risks. At the same time, the company plans to continue increasing investment, promote the expansion of its main business scale, and strive to break through the 300 million yuan threshold in revenue.

HILE previously disclosed on April 15, 2026, that it plans to establish a second-tier subsidiary, HILE Dental, through its controlling subsidiary Ruisheng Biology, to uniformly manage seven Jinboli dental chain stores in Yangzhou, Changzhou, and other locations, aiming to enhance overall profitability through the integration of oral medical service businesses. If HILE's financial indicators for 2026 still trigger relevant financial mandatory delisting situations, the company's shares will face the risk of termination of listing.